A Phase 3 interventional study of Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation and Lumify® (brimonidine tartrate ophthalmic solution 0.025%) in Ocular Redness, sponsored by Bausch & Lomb Incorporated. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-26.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preservative-free formulation, or Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will be treated with study drug for approximately 4 weeks.
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
First submitted after Bausch & Lomb Incorporated became part of Bausch Health Companies Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use any of the following disallowed medications during the period indicated prior to screening and for the duration of the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
Drug: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
Drug: Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
Ocular Redness
Ocular redness score evaluated by the investigator from 5 minutes to 240 minutes after investigational drug instillation (0-4 unit scale, where 0 = None and 4 = Extremely severe).
Time frame: Assessed at 5, 15, 30, 60, 90,120,180, 240 minutes post instillation.
| Milestone | Brimonidine Tartrate Preservation-free | Lumify® |
|---|---|---|
| Started | 190 | 190 |
| Completed | 165 | 179 |
| Not completed | 25 | 11 |
| Withdrew: Discontinued | 25 | 11 |
Ocular redness score evaluated by the investigator from 5 minutes to 240 minutes after investigational drug instillation (0-4 unit scale, where 0 = None and 4 = Extremely severe).
| score on a scale | Brimonidine Tartrate Preservation-free | Lumify® |
|---|---|---|
| 5 minutes Post Instillation | 0.46 ± 0.039 | 0.53 ± 0.041 |
| 15 minutes Post Instillation | 0.40 ± 0.038 | 0.49 ± 0.041 |
| 30 minutes Post Instillation | 0.42 ± 0.038 | 0.50 ± 0.041 |
| 60 minutes Post Instillation | 0.47 ± 0.040 | 0.52 ± 0.041 |
| 90 minutes Post Instillation | 0.54 ± 0.043 | 0.58 ± 0.044 |
| 120 minutes Post Instillation | 0.64 ± 0.046 | 0.67 ± 0.046 |
| 180 minutes Post Instillation | 0.79 ± 0.046 | 0.84 ± 0.049 |
| 240 minutes Post Instillation | 0.99 ± 0.047 | 0.98 ± 0.049 |
Collected over Through study completion, an average of 36 days.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brimonidine Tartrate Preservation-free | 0/188 (0%) | 0/188 (0%) | 13/188 (6.9%) |
| Lumify® | 0/190 (0%) | 1/190 (0.5%) | 18/190 (9.5%) |
| Event | Brimonidine Tartrate Preservation-free | Lumify® |
|---|---|---|
| SepsisInfections and infestations | 0/188 | 1/190 |
| Event | Brimonidine Tartrate Preservation-free | Lumify® |
|---|---|---|
| Instillation site painGeneral disorders | 6/188 | 6/190 |
| SinusitisInfections and infestations | 2/188 | 6/190 |
| Covid 19Infections and infestations | 5/188 | 2/190 |
| Visual acuity reducedEye disorders | 0/188 | 4/190 |
| Age, Categorical(Participants) | Brimonidine Tartrate Preservation-free | Lumify® | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 114 | 106 | 220 |
| >=65 years | 76 | 84 | 160 |
| Age, Continuous(years) | Brimonidine Tartrate Preservation-free | Lumify® | Total |
|---|---|---|---|
| Mean | 58.4 ± 14.65 | 59.5 ± 14.76 | 59 ± 14.70 |
| Sex: Female, Male(Participants) | Brimonidine Tartrate Preservation-free | Lumify® | Total |
|---|---|---|---|
| Female | 142 | 125 | 267 |
| Male | 48 | 65 | 113 |
| Ethnicity (NIH/OMB)(Participants) | Brimonidine Tartrate Preservation-free | Lumify® | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 17 | 29 |
| Not Hispanic or Latino | 178 | 173 | 351 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Brimonidine Tartrate Preservation-free | Lumify® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 4 | 5 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 46 | 43 | 89 |
| White | 138 | 138 | 276 |
| More than one race | 3 | 1 | 4 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Brimonidine Tartrate Preservation-free | Lumify® | Total |
|---|---|---|---|
| United States | 190 | 190 | 380 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2022 to primary completion in Nov 2022, 6 months.
Results were first posted in Aug 2024, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine